S&P Biotech ETF Harvest announced that the transaction price of the fund's secondary market was significantly higher than the reference net value of the fund share, and there was a large premium. On October 8, 2026, the closing price of the fund's secondary market was 1.572 yuan, and the reference net value of the fund share at the close was 1.4929 yuan. If the premium margin is not effectively reduced on October 9, 2026, the fund has the right to apply for measures such as temporary intraday suspension, extended suspension period, and continuous suspension to warn of risks. Currently, the fund is operating normally, and there is no material information that should be disclosed but not disclosed.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.